

Resource Summary Report

Generated by [NIF](#) on Sep 6, 2026

MCF-10A

RRID:CVCL_0598

Type: Cell Line

Proper Citation

RRID:CVCL_0598

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0598

Proper Citation: RRID:CVCL_0598

Description: Cell line MCF-10A is a Spontaneously immortalized cell line with a species of origin Homo sapiens (Human)

Sex: Female

Defining Citation: [PMID:1975513](#), [PMID:12661003](#), [PMID:15153330](#), [PMID:15375546](#), [PMID:16271952](#), [PMID:17157791](#), [PMID:17334996](#), [PMID:19582160](#), [PMID:20169162](#), [PMID:22414580](#), [PMID:24009699](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:24262153](#), [PMID:24389870](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25892236](#), [PMID:25960936](#), [PMID:26055192](#), [PMID:26218769](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:28287265](#), [PMID:28596718](#), [PMID:28889351](#), [PMID:29273624](#), [PMID:29444910](#), [PMID:29561695](#), [PMID:30787054](#), [PMID:32782317](#), [PMID:34238275](#), [PMID:35666001](#)

Comments: Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Spontaneously immortalized cell line

Organism: Homo sapiens (Human)

Name: MCF-10A

Synonyms: MCF 10A, MCF.10A, MCF10A, MCF10-A, MCF10a, MCF-10 Attached, Michigan Cancer Foundation-10A

Cross References: BTO:BTO_0001939, CLO:CLO_0007599, EFO:EFO_0001200, MCCL:MCC:0000305, AddexBio:C0006015/4976, ArrayExpress:E-MTAB-2706,

ArrayExpress:E-TABM-157, ATCC:CRL-10317, BCRJ:0161, BioGRID_ORCS_Cell_line:40, BioSample:SAMN03471375, cancercellines:CVCL_0598, CCRID:1101HUM-PUMC000406, CCRID:3101HUMSCSP575, ChEMBL-Cells:ChEMBL3307364, ChEMBL-Targets:ChEMBL614321, CLS:305026, Cosmic:1136376, Cosmic:1176649, Cosmic:2318371, Cosmic:2560254, DepMap:ACH-001357, EGA:EGAS00001000610, ENCODE:ENCBS066ENC, ENCODE:ENCBS067ENC, ENCODE:ENCBS317EPD, ENCODE:ENCBS417KGL, ENCODE:ENCBS617ENC, ENCODE:ENCBS618ENC, ENCODE:ENCBS619ENC, ENCODE:ENCBS620ENC, ENCODE:ENCBS621ENC, ENCODE:ENCBS622ENC, ENCODE:ENCBS623ENC, ENCODE:ENCBS868SSJ, GEO:GSM50033, GEO:GSM155217, GEO:GSM320171, GEO:GSM350543, GEO:GSM498022, GEO:GSM498026, GEO:GSM756371, GEO:GSM844584, GEO:GSM845395, GEO:GSM1053724, GEO:GSM1172882, GEO:GSM1172973, GEO:GSM1238116, GEO:GSM1328939, GEO:GSM1328940, GEO:GSM1328941, GEO:GSM2258704, GEO:GSM2258705, GEO:GSM2258706, GEO:GSM2258707, GEO:GSM2258708, GEO:GSM2258709, GEO:GSM2258710, GEO:GSM2258711, GEO:GSM2258712, GEO:GSM2258713, GEO:GSM2258714, GEO:GSM2258715, GEO:GSM2258716, GEO:GSM2258717, GEO:GSM2258718, GEO:GSM2258719, GEO:GSM2258720, GEO:GSM2258721, GEO:GSM2258944, GEO:GSM2258945, GEO:GSM2258946, GEO:GSM2862786, GEO:GSM2862787, GEO:GSM2862788, IARC_TP53:24292, IBRC:C10788, IGRhCellID:MCF10A, IZSLER:BS CL 174, KCB:KCB 2014066YJ, LINCS_HMS:50583, LINCS_LDP:LCL-2085, Lonza:131, MetaboLights:MTBLS401, NCBI_Iran:C609, PharmacDB:MCF10A_891_2019, PRIDE:PXD000309, PRIDE:PXD000593, PRIDE:PXD000691, PRIDE:PXD003370, PRIDE:PXD005339, PRIDE:PXD008222, PRIDE:PXD009668, PRIDE:PXD028400, Progenetix:CVCL_0598, PubChem_Cell_line:CVCL_0598, TOKU-E:2378, Wikidata:Q54904280

ID: CVCL_0598

Hierarchy: cvcl_3633

Record Creation Time: 20220427T220750+0000

Record Last Update: 20260905T181113+0000

Ratings and Alerts

No rating or validation information has been found for MCF-10A.

No alerts have been found for MCF-10A.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6422 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Przanowska R, et al. (2026) IL-6R blockade with tocilizumab disrupts pericyte- and tumor cell-driven IL-6/STAT3 signaling, enhancing docetaxel efficacy in ER+ breast cancer. *bioRxiv : the preprint server for biology*.

Pyun WY, et al. (2026) Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. *Cancer research*, 86(5), 1194.

Yang Z, et al. (2026) Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer. *Cell reports. Medicine*, 7(2), 102613.

Kim NY, et al. (2026) HER2-dependent paraptosis and ferroptosis induction by cannabidiol in breast cancer cells. *Biochimica et biophysica acta. Molecular basis of disease*, 1872(4), 168177.

Yang T, et al. (2026) Covalent Inhibition of SHMT2 by Gambogic Acid Induces Ferroptosis Through Mitochondrial Collapse in Triple-Negative Breast Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(42), e20252.

Cando LF, et al. (2026) Targeting microRNA let-7b-5p-mediated aberrant androgen receptor signaling for prevention of hormone receptor-negative breast cancer. *NPJ breast cancer*.

Russo MR, et al. (2026) Protocol for cell cycle-resolved high-content imaging of transcription condensate dynamics in human cells. *STAR protocols*, 7(2), 104589.

Mathieu C, et al. (2026) Inhibition of TRAP1 in the C-terminal domain influences mitochondria properties and breast cancer cell metabolism. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 196, 119060.

Marmolejo CO, et al. (2026) Precise control of transcription condensates across S phase balances linker histone expression with DNA replication, ensuring genome stability. *Molecular cell*, 86(4), 640.

Alheety NF, et al. (2026) Integrated DFT, Molecular Docking, and In Silico ADME Analysis of New Benzimidazole Derivatives as Promising Anticancer Candidates Targeting MCF-7 Cells. *Chemistry & biodiversity*, 23(2), e03385.

Xiao X, et al. (2026) Single-Mitochondrion ATP Profiling Directs Discovery of Targetable OXPHOS Dependency in Cancers. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(21), e13341.

Li X, et al. (2026) Integration of Demethylation-Switchable Deoxyribozyme with Controllable Self-Assembly of Branched DNA Nanostructures Enables In Situ Monitoring of FTO Demethylation in Living Cells. *Analytical chemistry*, 98(7), 5614.

den Hollander P, et al. (2026) EMT-induced stem cell and mesenchymal programs can be decoupled via cell division and ESRP1-dependent mechanisms. *iScience*, 29(1), 114284.

Yang DM, et al. (2026) Isolation, Structural Elucidation, and Biological Evaluation of Homoisoflavonoids From *Pterolobium Macropterum*. *Chemistry & biodiversity*, 23(4),

e71207.

Berardi V, et al. (2026) Regulatory BC200 RNA promotes breast carcinogenesis by repressing BRCA1 gene expression. *iScience*, 29(4), 115267.

Venkatesh J, et al. (2026) LINC01929 mediates breast cancer immunosuppression and is an immunotherapy target. *iScience*, 29(4), 115381.

Rivera-Caraballo KA, et al. (2026) Oncolytic HSV-1-Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis. *Cancer research*, 86(5), 1232.

Eason M, et al. (2026) Delivery of Pleckstrin-Homology Domains Suppresses PI3K/Akt Signaling and Breast Cancer Metastasis. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(30), e18339.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Chatterjee E, et al. (2026) Autophagy-lysosomal dependency defines a vulnerable physiological state in drug-tolerant persister cells of triple-negative breast cancer. *Apoptosis : an international journal on programmed cell death*, 31(5).